Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

April 05, 2016; 86 (16 Supplement) April 18, 2016

High Dose Biotin as Treatment for Progressive Multiple Sclerosis (P3.039)

Gary Birnbaum, Jessica Stulc, Tori Snyder
First published April 4, 2016,
Gary Birnbaum
3MS Treatment & Research Center Golden Valley MN United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jessica Stulc
1Golden Valley MN United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tori Snyder
2MS Treatment and Research Center Minneapolis Clinic of Neurology Golden Valley MN United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
High Dose Biotin as Treatment for Progressive Multiple Sclerosis (P3.039)
Gary Birnbaum, Jessica Stulc, Tori Snyder
Neurology Apr 2016, 86 (16 Supplement) P3.039;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: To determine the efficacy and tolerability of high dose biotin in persons with progressive MS. Background: High doses of biotin are reported to improve neurologic function in a small percentage of persons with progressive MS. We wished to document these potential benefits in a “real world” MS specialty clinic. Design/Methods: Three groups of patients with clinically definite multiple sclerosis were evaluated, those with relapses well controlled on disease-modifying therapy yet having progressive disability, patients with secondary progressive MS, no longer on disease-modifying therapy, and patients with primary progressive multiple sclerosis. High dose, pharmaceutical grade biotin, in 300 mg capsules, was prepared by a compounding pharmacy, One capsule per day was prescribed. Neurologic exams and blood work monitoring for toxicity were obtained at baseline and at three-month intervals on drug. Brain MRIs were obtained at baseline and after one year on biotin. Results: Twenty one patients were treated, eleven with secondary progressive MS, four with primary progressive MS, and six patients with relapsing remitting MS. Ten patients were on various disease-modifying therapies. There were 10 males and 11 females, ranging in age from 41 to 74 years. EDSS scores ranged from 4 to 6.5. To date, no patient experienced an adverse event. Of patients evaluated at three months, one patient’s EDSS improved from 6.5 to 6.0, with resolution of arthritic pain. One patient noted greatly improved energy with a 10[percnt] improvement in 25-foot timed walk. Data on all patients at nine-month and twelve-month exams will be presented. Conclusion: High dose biotin, administered daily to persons with progressive MS is well tolerated and results in improvement of neurologic function is a subset of such individuals.

Disclosure: Dr. Birnbaum received research support from Biogen-Idec and Hoffman-LaRoche. Dr. Stulc has nothing to disclose. Dr. Snyder has nothing to disclose.

Monday, April 18 2016, 8:30 am-7:00 pm

  • Copyright © 2016 by AAN Enterprises, Inc.

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 96 (15)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2021 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise